To include your compound in the COVID-19 Resource Center, submit it here.

When ImClone knew

In testimony to Congress on Thursday, IMCL President and CEO Harlan Waksal acknowledged that he, his brother Samuel Waksal, and other IMCL executives knew in mid-December that FDA was seriously considering rejecting the BLA for the company's Erbitux antibody to treat colorectal cancer, and that IMCL had detailed knowledge of FDA's decision to issue a

Read the full 550 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers